May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden Demands Pfizer’s Compliance with Committee’s Pharma Tax Investigation
- Wyden asks DOJ to Investigate Medicaid Fraud by Youth Residential Treatment Facilities and Potential Civil Rights Violations by States
- Wyden Announces Virginia Lenahan as Finance Committee Chief International Trade Counsel
- Wyden and Brown Urge FTC to Investigate Emerging Anti-Competitive Practices by PBMs
- Wyden and Hassan Lead Introduction of Legislation to Stop Labor and Delivery Unit Closures in Rural and Underserved Communities